Exploring non-invasive diagnostics for metabolic dysfunctionassociated fatty liver disease  

作　　者：Biao Qu Zheng Li 

机构地区：[1]Department of Clinical Pharmacology,The Second Hospital of Anhui Medical University,Hefei 230601,Anhui Province,China [2]Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells,College of Health Sciences,School of Life Sciences,Jiangsu Normal University,Xuzhou 221000,Jiangsu Province,China

出　　处：《World Journal of Gastroenterology》2024年第28期3447-3451,共5页世界胃肠病学杂志（英文版）

基　　金：Supported by The National Natural Science Foundation of China,No.82104525.

摘　　要：The population with metabolic dysfunction-associated fatty liver disease(MAFLD)is increasingly common worldwide.Identification of people at risk of progression to advanced stages is necessary to timely offer interventions and appropriate care.Liver biopsy is currently considered the gold standard for the diagnosis and staging of MAFLD,but it has associated risks and limitations.This has spurred the exploration of non-invasive diagnostics for MAFLD,especially for steatohepatitis and fibrosis.These non-invasive approaches mostly include biomarkers and algorithms derived from anthropometric measurements,serum tests,imaging or stool metagenome profiling.However,they still need rigorous and widespread clinical validation for the diagnostic performance.

关 键 词：Metabolic dysfunction-associated fatty liver disease Non-invasive diagnostics Circulating biomarkers Imaging biomarkers Stool microbial biomarkers 

分 类 号：R575.5[医药卫生—消化系统]